↓ Skip to main content

Synthetically lethal nanoparticles for treatment of endometrial cancer

Overview of attention for article published in Nature Nanotechnology, December 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
24 news outlets
blogs
4 blogs
twitter
17 X users
facebook
1 Facebook page

Citations

dimensions_citation
59 Dimensions

Readers on

mendeley
93 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Synthetically lethal nanoparticles for treatment of endometrial cancer
Published in
Nature Nanotechnology, December 2017
DOI 10.1038/s41565-017-0009-7
Pubmed ID
Authors

Kareem Ebeid, Xiangbing Meng, Kristina W. Thiel, Anh-Vu Do, Sean M. Geary, Angie S. Morris, Erica L. Pham, Amaraporn Wongrakpanich, Yashpal S. Chhonker, Daryl J. Murry, Kimberly K. Leslie, Aliasger K. Salem

Abstract

Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 93 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 16%
Student > Master 12 13%
Researcher 11 12%
Student > Bachelor 6 6%
Student > Doctoral Student 5 5%
Other 22 24%
Unknown 22 24%
Readers by discipline Count As %
Chemistry 15 16%
Biochemistry, Genetics and Molecular Biology 9 10%
Medicine and Dentistry 9 10%
Agricultural and Biological Sciences 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Other 19 20%
Unknown 27 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 213. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2021.
All research outputs
#169,796
of 24,257,370 outputs
Outputs from Nature Nanotechnology
#102
of 3,595 outputs
Outputs of similar age
#3,858
of 447,487 outputs
Outputs of similar age from Nature Nanotechnology
#5
of 67 outputs
Altmetric has tracked 24,257,370 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,595 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.